BY MOUTH, 2.5 - 10 MG DAILY FOR 5 - 10 DAYS BEGINNING ON DAY 16 TO 21 OF CYCLE, REPEATED FOR 2 CYCLES IN DYSFUNCTIONAL UTERINE BLEEDING AND 3 CYCLES IN SECONDARY AMENORRHOEA
MILD TO MODERATE ENDOMETRIOSIS, 10 MG 3 TIMES DAILY FOR 90 CONSECUTIVE DAYS, BEGINNING ON DAY 1 OF CYCLE BY MOUTH
ENDOMETRIOSIS :- 10 MG DAILY OR 50 MG WEEKLY OR 100 MG EVERY 2 WEEKS BY I.M. INJECTION.
IT IS ALSO GIVEN BY I.M. INJECTION AS A PROGESTOGEN-ONLY CONTRACEPTIVE AT A DOSE OF 150 MG EVERY 12 WEEKS.
PROGESTOGENIC OPPOSITION OF OESTROGEN HRT, 10 MG DAILY FOR THE LAST 14 DAYS OF EACH 28-DAY OESTROGEN HRT CYCLE
PALLIATIVE TREATMENT OF SOME HORMONE-DEPENDENT MALIGNANT NEOPLASMS. IN BREAST CARCINOMA DOSES OF 0.4 TO 1.5 G DAILY BY MOUTH MAY BE GIVEN, ALTHOUGH DOSES UP TO 2 G DAILY HAVE BEEN USED IN THE PAST. INTRAMUSCULAR MEDROXYPROGESTERONE ACETATE HAS BEEN GIVEN IN INITIAL DOSES OF 0.5 TO 1 G DAILY FOR 4 WEEKS, AND IN MAINTENANCE DOSES OF 0.5 G TWICE WEEKLY. IN ENDOMETRIAL AND RENAL CARCINOMA DOSES HAVE RANGED FROM 200 TO 600 MG DAILY BY MOUTH. INITIAL DOSES OF 0.4 TO 1 G WEEKLY HAVE BEEN GIVEN BY INTRAMUSCULAR INJECTION, REDUCING TO A MAINTENANCE SCHEDULE OF AS LITTLE AS 0.4 G MONTHLY. IN PROSTATIC CARCINOMA DOSES HAVE BEEN 100 TO 600 MG DAILY BY MOUTH; 500 MG HAS ALSO BEEN GIVEN BY INTRAMUSCULAR INJECTION, INITIALLY TWICE WEEKLY FOR 3 MONTHS THEN ONCE WEEKLY FOR MAINTENANCE.